Paper

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

Multiple Sclerosis Journal · 2025 · Jeffrey A Cohen, Douglas L Arnold, John DeLuca et al.